Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 12/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | IDH2 | P48735 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063180 | 1.00 | ASGR1 (0.52) | ASGR1HCRTR1HCRTR2IRAK4TAS2R14 | |
| SCHEMBL26879879 | 0.85 | ASGR1 (0.52) | ASGR1 | |
| SCHEMBL30063132 | 0.83 | ASGR1 (0.54) | ASGR1HCRTR1 | |
| SCHEMBL24724890 | 0.83 | ASGR1 (0.54) | ASGR1HCRTR1 | |
| SCHEMBL31376882 | 0.82 | ASGR1 (0.36) | ASGR1HCRTR1HCRTR2IRAK4TAS2R14 | |
| SCHEMBL31376879 | 0.82 | ASGR1 (0.46) | ASGR1HCRTR1HCRTR2IRAK4 | |
| SCHEMBL24725115 | 0.82 | ASGR1 (0.35) | ASGR1HCRTR1HCRTR2 | |
| SCHEMBL24725419 | 0.81 | ASGR1 (0.34) | ASGR1HCRTR1HCRTR2 | |
| SCHEMBL31726478 | 0.79 | ASGR1 (0.37) | ASGR1HCRTR1HCRTR2IRAK4TAS2R14 | |
| SCHEMBL31376897 | 0.78 | ASGR1 (0.45) | ASGR1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2023028338-A2 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312340-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | ASGR1 1/4885HCRTR1 3545/4885HCRTR2 3526/4885 |
| US-20240279209-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | ASGR1 1/4885HCRTR1 3545/4885HCRTR2 3526/4885 |
| US-12091402-B2 | Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins | ASGR1, FCGR2A, FCGR3B | ASGR1 1/4885HCRTR1 3545/4885HCRTR2 3526/4885 |
| US-20250223280-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | ASGR1 1/4885HCRTR1 3545/4885HCRTR2 3526/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | ASGR1 2/4885HCRTR1 3610/4885HCRTR2 3737/4885 |
| US-20240101539-A1 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | ASGR1 1/4885HCRTR1 3545/4885HCRTR2 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.